Biography:
Jack Rogers, PhD. is a leading authority on the maintenance of iron homeostasis related to investigating its modulatory action on RNA metabolism in disease processes in neurodegeneration, including manganese neurotoxicity and Parkinson’s disease (PD). He is the co-Director of the Neurochemistry Program in the Psychiatry/ NEUROSCIENCE Department at Massachusetts General Hospital. Jack works closely with his partner Dr. Catherine Cahill in their joint effort for establishing novel therapies to treat and retard iron imbalances and ferroptosis that can accelerate the neurodegeneration of PD and Alzheimer’s Disease. He is an Associate Professor at the Harvard Medical School, having a funded track-record in established scientific journals (Cell, J. Biol. Chem. and PNAS.). His peer review publications won him a Zenith award from the Alzheimer’s Association on translational control by iron and related disease progression. The team is contributing efforts for small molecule drug discovery for treatments of neurodegenerative and neurodevelopmental disease. They are advancing novel pharmacological therapies in order to offset the manganese induced neurotoxicity that can generate Parkinsonian ferroptosis and undermine neural survival.
Title : Translation modulators to preserve neurodegenerative decline and from metal toxicity (Part II)
Title : Translation modulators to preserve neurodegenerative decline from metal toxicity
Title : Urate restores APP translational expression and losses of neural cell viability from Mn exposure